Cure Alzheimer's Fund Cure Alzheimer's Fund

Support of Cerebrospinal Fluid Biomarker Study–ADNI

2007

Cure Alzheimer’s Fund is part of a funding consortium supporting collaborative biomarker investigation of the elevation of tau and decreased concentrations of Amyloid beta 42 in the cerebrospinal fluid (CSF) as evidence of the presence of the Alzheimer’s disease pathology.

Biomarkers/Diagnostics/Studies of Risk & Resilience Foundational John Q. Trojanowski Leslie M. Shaw

Funding to Date

$100,000

Focus

Biomarkers/Diagnostics/Studies of Risk & Resilience, Foundational

Researchers

John Q. Trojanowski, M.D., Ph.D.

Leslie M. Shaw, Ph.D.

Related Content:


Plasma Proteins, Sex and Alzheimer’s Disease: Proteome-Wide Analyses of the UK Biobank and Framingham Heart Study P. Murali Doraiswamy 2024-12-16 Relationship Between Alzheimer’s Disease Risk Score and Outcomes of Mild Repetitive Neurotrauma Thomas McAllister Michael McCrea 2024-12-16 Alzheimer’s Disease PET Imaging of Nonfibrillar Amyloid Beta Aggregates Using Azapeptide (AZP) Tracer Sam Gandy Brigitte Guérin Shai Rahimipour William Lubell 2024-12-16 Midlife Autoantibody Profiles and the Risk of Late-Onset Alzheimer’s Disease in Women Yu Chen 2024-10-31 Bioinformatics Platform for Modeling Alzheimer’s Progression (MAP-AD Platform) Ali Ezzati 2024-09-16 Understanding Human Brain Resilience to Alzheimer’s Pathology Teresa Gomez-Isla 2024-08-19 Utility of Blood-Based Markers for Predicting Amyloid-Related Imaging Abnormalities and Their Course in Mild Cognitive Impairment and Alzheimer’s Disease Subjects Undergoing Routine Clinical Treatment with Amyloid-Directed Antibodies P. Murali Doraiswamy 2024-01-12 Characterization of the Longitudinal Trajectories of the Synaptic Blood Marker Beta-Synuclein During Alzheimer’s Disease Pathogenesis and Improvement of the Measurement Procedure Patrick Oeckl Markus Otto 2023-09-19